益丰药房(603939) - 2017 Q3 - 季度财报

Financial Performance - Operating revenue for the first nine months reached CNY 3,418,989,164.04, a growth of 27.93% year-on-year[6] - Net profit attributable to shareholders increased by 38.16% to CNY 220,185,592.29 for the first nine months[6] - Basic earnings per share increased by 25.41% to CNY 0.607[8] - The company reported a significant increase in goodwill, rising to CNY 598,558,706.44 from CNY 529,228,706.44, which is an increase of about 13.1%[20] - Total operating revenue for Q3 2017 reached RMB 1,180,387,998.60, a 29.7% increase from RMB 909,839,774.79 in the same period last year[26] - Net profit attributable to the parent company for Q3 2017 was RMB 65,387,238.01, an increase of 38.3% from RMB 47,264,384.13 in the same quarter last year[28] - The company reported a total profit of RMB 90,254,111.46 for Q3 2017, up 39.7% from RMB 64,558,863.44 in Q3 2016[27] - The year-to-date net profit from January to September 2017 was ¥154,077,077.28, an increase of 94.06% compared to ¥79,378,661.09 in the same period last year[31] Cash Flow - The net cash flow from operating activities rose by 35.98% to CNY 244,778,989.66 year-on-year[6] - The company's operating cash flow for the first nine months of 2017 was ¥244,778,989.66, up from ¥180,010,158.99 in the same period last year, indicating a growth of 36%[33] - Total cash inflow from investment activities was CNY 2,819,696,690.81, compared to CNY 1,548,804,889.25 in the previous year, indicating a significant increase of about 82.2%[36] - Cash outflow from investment activities totaled CNY 2,748,407,550.57, down from CNY 2,827,253,088.34 year-over-year, reflecting a decrease of approximately 2.8%[36] - The net increase in cash and cash equivalents for the period was CNY 35,333,785.82, down from CNY 93,930,026.36 in the same period last year[37] Assets and Liabilities - Total assets increased by 7.16% to CNY 4,523,483,438.50 compared to the end of the previous year[6] - Total liabilities increased to CNY 1,437,969,703.55 from CNY 1,245,897,751.02, marking an increase of around 15.4%[21] - Owner's equity grew to CNY 3,085,513,734.95 from CNY 2,975,348,493.88, which is an increase of about 3.7%[21] - Current assets totaled CNY 3,216,069,024.19, up from CNY 3,125,717,969.07, indicating an increase of about 2.9%[20] - Non-current assets rose to CNY 1,307,414,414.31 from CNY 1,095,528,275.83, reflecting a growth of approximately 19.3%[20] Shareholder Information - The company had a total of 9,569 shareholders at the end of the reporting period[11] - The largest shareholder, Hunan Yifeng Pharmaceutical Investment Management Co., Ltd., holds 29.27% of the shares[11] Operational Expansion - The company reported a net increase of 107 stores in Q3 2017, including 81 new openings and 18 acquisitions, bringing the total to 1,890 stores[14] - The company completed two new acquisition projects during the reporting period, including the purchase of 42 retail pharmacies for approximately ¥41.88 million[15] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[28] Cost and Expenses - Total operating costs for the first nine months of 2017 were RMB 3,127,086,739.87, an increase of 27.0% from RMB 2,462,180,198.34 in the previous year[26] - The company’s management expenses rose by 30.26% to ¥139,110,092.65, primarily due to expanded operational scale[13] - Sales expenses for Q3 2017 were ¥115,040,373.00, down 4.78% from ¥120,958,101.42 in Q3 2016[30]